Affimed N.V. (AFMD)
NASDAQ: AFMD · Real-Time Price · USD
0.7811
-0.0239 (-2.97%)
At close: Mar 28, 2025, 4:00 PM
0.7877
+0.0065 (0.84%)
After-hours: Mar 28, 2025, 7:55 PM EDT
Affimed Employees
Affimed had 76 employees as of December 31, 2023. The number of employees decreased by 143 or -65.30% compared to the previous year.
Employees
76
Change (1Y)
-143
Growth (1Y)
-65.30%
Revenue / Employee
$82,725
Profits / Employee
-$1,026,832
Market Cap
12.80M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AFMD News
- 5 days ago - Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting - GlobeNewsWire
- 27 days ago - Affimed to Present at the Leerink Partners Global Healthcare Conference 2025 - GlobeNewsWire
- 3 months ago - Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) - GlobeNewsWire
- 3 months ago - Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer - GlobeNewsWire
- 4 months ago - Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients - GlobeNewsWire
- 4 months ago - Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA) - GlobeNewsWire
- 4 months ago - Affimed N.V. (AFMD) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Affimed Reports Third Quarter 2024 Financial Results & Business Update - GlobeNewsWire